MedPath

Interest of Challenge Tests for Diagnosis of Immediate Hypersensitivity Against Iodinated Contrast Agents

Completed
Conditions
Allergic Reaction
Registration Number
NCT03525496
Lead Sponsor
Centre Hospitalier Régional Metz-Thionville
Brief Summary

Iodinated contrast agents (ICA) are widely used in medical imaging. They provide however a risk of immediate hypersensitivity reactions (IHS). The risk of anaphylactic shock is estimated at 1/100 000 injections. Nevertheless, for safety reasons and to limit undesirable effects, the reintroduction tests are not conducted along similar lines to throughout scan or arteriography. Moreover, reintroduction protocols are actually not standardized, in terms of injected volume and doses progression. It should be evaluated the relevance of the reintroduction tests with injection of a low volume and ensure the absence of reaction during the ICA injections Under real conditions.

The investigators are assuming that the realization of a provocation test by intravenous reintroduction with a reduced dose of ICA improves the predictive value of IHS in comparison with only cutaneous tests.

Detailed Description

The main objective of this study will be to estimate the negative predictive value of the combination of cutaneous tests and provocation test by intravenous reintroduction in the IHS to iodinated contrast agents.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
85
Inclusion Criteria
  • Major patient
  • Having suffered single-blind reintroduction
  • Having benefited from cutaneous tests and ICA reintroduction test in the framework of IHS
Exclusion Criteria
  • Patient with delayed hypersensitivity
  • Opposed to use data

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Percentage of immediate hypersensitivity reactionsDay 1

Occurrence of immediate hypersensitivity reactions after an injection of ICA

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

CHR Metz-Thionville

🇫🇷

Metz, Moselle, France

CHR Metz-Thionville
🇫🇷Metz, Moselle, France

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.